885 related articles for article (PubMed ID: 1535088)
21. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
22. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
23. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
24. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
25. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
26. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
Gorelik E; Gunji Y; Herberman RB
J Immunol; 1988 Mar; 140(6):2096-102. PubMed ID: 3126240
[TBL] [Abstract][Full Text] [Related]
27. Costimulatory signals are required for optimal proliferation of human natural killer cells.
Robertson MJ; Manley TJ; Donahue C; Levine H; Ritz J
J Immunol; 1993 Mar; 150(5):1705-14. PubMed ID: 7679691
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
29. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
30. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
31. Regulation of CD3- lymphocyte function with an antibody against the IL-2 beta chain receptor: modulation of NK and LAK activity and production of IFN gamma.
Ortaldo JR; Frey J; Takeshita T; Sugamura K
Eur Cytokine Netw; 1990; 1(1):27-34. PubMed ID: 2151685
[TBL] [Abstract][Full Text] [Related]
32. The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone.
Hayakawa K; Salmeron MA; Kornbluth J; Bucana C; Itoh K
J Immunol; 1991 Apr; 146(7):2453-60. PubMed ID: 1900882
[TBL] [Abstract][Full Text] [Related]
33. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
34. Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer.
Whiteside TL; Chikamatsu K; Nagashima S; Okada K
Anticancer Res; 1996; 16(4C):2357-64. PubMed ID: 8816835
[TBL] [Abstract][Full Text] [Related]
35. Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells.
Aste-Amezaga M; D'Andrea A; Kubin M; Trinchieri G
Cell Immunol; 1994 Jul; 156(2):480-92. PubMed ID: 7912999
[TBL] [Abstract][Full Text] [Related]
36. Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity.
Giovarelli M; Santoni A; Jemma C; Musso T; Giuffrida AM; Cavallo G; Landolfo S; Forni G
J Immunol; 1988 Oct; 141(8):2831-6. PubMed ID: 3139768
[TBL] [Abstract][Full Text] [Related]
37. Cord blood CD16+56- cells with low lytic activity are possible precursors of mature natural killer cells.
Gaddy J; Broxmeyer HE
Cell Immunol; 1997 Sep; 180(2):132-42. PubMed ID: 9341743
[TBL] [Abstract][Full Text] [Related]
38. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
[TBL] [Abstract][Full Text] [Related]
39. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
40. IFN-gamma-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones.
Tsutsui H; Nakanishi K; Matsui K; Higashino K; Okamura H; Miyazawa Y; Kaneda K
J Immunol; 1996 Nov; 157(9):3967-73. PubMed ID: 8892629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]